Scientific Opinion on the substantiation of health claims related to lactulose and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 806) and reduction in intestinal transit time (ID 807) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

被引：4

作者：

Agostoni, Carlo ^{[1
]}

Bresson, Jean-Louis ^{[1
]}

Fainveather-Tait, Susan ^{[1
]}

Flynn, Albert ^{[1
]}

Golly, Ines ^{[1
]}

Korhonen, Harmu ^{[1
]}

Lagiou, Pagona ^{[1
]}

Lovik, Martinus ^{[1
]}

Marchelli, Rosangela ^{[1
]}

Martin, Ambroise ^{[1
]}

Moseley, Bevan ^{[1
]}

Neuhaeuser-Berthold, Monika ^{[1
]}

Przyrembel, Hildegard ^{[1
]}

Salminen, Seppo ^{[1
]}

Sanz, Yolanda ^{[1
]}

Strain, Sean ^{[1
]}

Strobel, Stephan ^{[1
]}

Tetens, Inge ^{[1
]}

Tome, Daniel ^{[1
]}

van Loveren, Hendrik ^{[1
]}

Verhagen, Hans ^{[1
]}

机构：

[1] EFSA, Parma, Italy

来源：

EFSA JOURNAL | 2010年 / 8卷 / 10期

关键词：

Lactulose; intestinal transit time; potentially pathogenic microorganisms; health claims;

D O I：

10.2903/j.efsa.2010.1806

中图分类号：

TS2 [食品工业];

学科分类号：

0832 ;

摘要：

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims in relation to lactulose and decreasing potentially pathogenic gastro-intestinal microorganisms and reduction in intestinal transit time. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders. The food constituent that is the subject of the health claims is lactulose. The Panel considers that lactulose is sufficiently characterised. Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 806) The claimed effect is "probiotic/bifidogenic". The target population is assumed to be the general population. In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the capacity of the food constituent to increase the numbers of bacteria that are considered to be "healthy/balanced/good".Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims in relation to lactulose and decreasing potentially pathogenic gastro-intestinal microorganisms and reduction in intestinal transit time. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders. The food constituent that is the subject of the health claims is lactulose. The Panel considers that lactulose is sufficiently characterised. Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 806) The claimed effect is "probiotic/bifidogenic". The target population is assumed to be the general population. In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the capacity of the food constituent to increase the numbers of bacteria that are considered to be "healthy/balanced/good". The Panel considers that the evidence provided does not establish that increasing the numbers of gastro-intestinal microorganisms is a beneficial physiological effect. The Panel considers that the claimed effect in the context of decreasing potentially pathogenic gastrointestinal microorganisms might be a beneficial physiological effect. No references were provided from which conclusions could be drawn for the scientific substantiation of the claimed effect. On the basis of the data presented, the Panel concludes that a cause and effect relationship has not been established between the consumption of lactulose and decreasing potentially pathogenic gastrointestinal microorganisms. Reduction in intestinal transit time (ID 807) The claimed effect is "transit effect". The target population is assumed to be the general population. In the context of the proposed wordings, the Panel assumes that the claimed effect refers to improvement of intestinal transit time. The Panel considers that a reduction in intestinal transit time within the normal range might be a beneficial physiological effect. In weighing the evidence, the Panel took into account that all studies provided showed a consistent statistically significant effect of lactulose at a dose of 10 g per day on reduction in intestinal transit time, and that the mechanism by which lactulose could exert the claimed effect is established. On the basis of the data presented, the Panel concludes that a cause and effect relationship has been established between the consumption of lactulose and a reduction in intestinal transit time. The Panel considers that in order to obtain the claimed effect at least 10 g of lactulose per day should be consumed in a single serving. The target population is the general population.

引用

页数：15

共 10 条

[1] Effects of lactulose and lactitol on colonic microflora and enzymatic activity [J].